Supraflex Cruz: Revolutionizing Interventional Cardiology with New Clinical Insights

Sahajanand Medical Technologies (SMT) has unveiled compelling results from four pivotal clinical trials that highlight the efficacy and safety of the Supraflex Cruz drug-eluting stent. The data, presented at the TCT 2025 conference, emphasize Supraflex Cruz's effectiveness across various challenging patient demographics, reinforcing its role in advanced interventional cardiology.

Sahajanand Medical Technologies (SMT) has announced promising findings from four landmark clinical studies presented at the TCT 2025 conference. These studies confirm the Supraflex Cruz drug-eluting stent's safety and consistency across complex patient cases.

The TUXEDO II trial, which included 1,800 diabetic patients with multivessel disease, demonstrated that Supraflex Cruz had comparable clinical outcomes to Xience, affirming its reliable performance. Similarly, the Multivessel TALENT trial showed that Supraflex Cruz confirmed its non-inferiority in three-vessel coronary artery disease compared to Synergy, particularly in patients with more complex conditions.

Cruz Senior Study highlighted successful and safe outcomes for patients over 80 years of age, while the SFlex Netherlands Registry reinforced the stent's reliable performance in real-world settings. Combined, these studies solidify the Supraflex Cruz's position as a next-generation stent in interventional cardiology.